S. Z. Goldhaber and H. Bounameaux, Pulmonary embolism and deep vein thrombosis, Lancet, vol.379, pp.1835-1846, 2012.

G. Cocco, P. Amiet, and P. Jerie, Antithromboembolic strategies in atrial fibrillation: A review, Cardiol. J, 2016.

R. Rossini, G. Musumeci, and C. Lettieri, Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy, Am. J. Cardiol, vol.102, pp.1618-1623, 2008.

P. Pouyanne, F. Haramburu, J. L. Imbs, and B. Bégaud, Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres, BMJ, vol.320, p.1036, 2000.

A. Bénard-laribière, G. Miremont-salamé, and M. Pérault-pochat, Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study

, Fundam. Clin. Pharmacol, vol.29, pp.106-117, 2015.

S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine, Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines, Chest, issue.6, p.133, 2008.

L. Linkins, P. T. Choi, and J. D. Douketis, Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis, Ann. Intern. Med, vol.139, pp.893-900, 2003.

Y. Gruel and A. Maakaroun, Rev. Prat, vol.52, pp.1929-1964, 2002.

B. Boneu and P. Léger, Oral anticoagulant treatment: practical aspects and significance of anticoagulant clinics

, Ann. Cardiol. Angeiol, vol.51, pp.164-172, 2002.

, Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation, Arch. Intern. Med, vol.154, pp.1449-57, 1994.

M. L. Flaherty, B. Kissela, and D. Woo, The increasing incidence of anticoagulantassociated intracerebral hemorrhage, Neurology, vol.68, pp.116-137, 2007.

M. Shoeb and M. C. Fang, Assessing Bleeding Risk in Patients Taking Anticoagulants, J. Thromb. Thrombolysis, vol.35, pp.312-319, 2013.

A. Gómez-outes, M. L. Suárez-gea, R. Lecumberri, A. I. Terleira-fernández, and E. Vargas-castrillón, Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. Vasc. Health Risk Manag, vol.10, pp.627-639, 2014.

S. J. Connolly, J. Eikelboom, and C. Joyner, Apixaban in patients with atrial fibrillation, N. Engl. J. Med, vol.364, pp.806-817, 2011.

C. B. Granger, J. H. Alexander, and J. V. Mcmurray, Apixaban versus warfarin in patients with atrial fibrillation, N. Engl. J. Med, vol.365, pp.981-992, 2011.

S. J. Connolly, M. D. Ezekowitz, and S. Yusuf, Dabigatran versus warfarin in patients with atrial fibrillation, N. Engl. J. Med, vol.361, pp.1139-1151, 2009.

S. J. Connolly, M. D. Ezekowitz, and S. Yusuf, Newly identified events in the RE-LY trial, N. Engl. J. Med, vol.363, pp.1875-1881, 2010.

S. Schulman, C. Kearon, and A. K. Kakkar, Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N. Engl. J. Med, vol.361, pp.2342-52, 2009.
URL : https://hal.archives-ouvertes.fr/ujm-00439704

S. Schulman, A. K. Kakkar, and S. Z. Goldhaber, Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis, Circulation, vol.129, pp.764-772, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01030866

S. Schulman, C. Kearon, and A. K. Kakkar, Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism, N. Engl. J. Med, vol.368, pp.709-718, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00935796

M. R. Patel, K. W. Mahaffey, and J. Garg, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N. Engl. J. Med, vol.365, pp.883-91, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01038111

. Einstein-investigators, R. Bauersachs, and S. D. Berkowitz, Oral rivaroxaban for symptomatic venous thromboembolism, N. Engl. J. Med, vol.363, pp.2499-510, 2010.

C. B. Granger, J. H. Alexander, and J. Mcmurray, Apixaban versus warfarin in patients with atrial fibrillation, N. Engl. J. Med, vol.365, pp.981-92, 2011.

G. C. Flaker, J. W. Eikelboom, and O. Shestakovska, Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin: The Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin k Antagonist Treatment (AVERROES) Trial, Stroke, vol.43, pp.3291-3297, 2012.

G. Agnelli, H. R. Buller, and A. Cohen, Oral Apixaban for the Treatment of Acute Venous Thromboembolism, N. Engl. J. Med, vol.369, pp.799-808, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00932477

-. Hokusai, . Investigators, H. R. Büller, and H. Décousus, Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N. Engl. J. Med, vol.369, pp.1406-1421, 2013.

R. P. Giugliano, C. T. Ruff, and E. Braunwald, Edoxaban versus Warfarin in Patients with Atrial Fibrillation, N. Engl. J. Med, vol.369, pp.2093-2104, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00934699

J. Berwaerts and J. Webster, Analysis of risk factors involved in oral-anticoagulantrelated intracranial haemorrhages, QJM, vol.93, pp.513-534, 2000.

E. M. Hylek and D. E. Singer, Risk factors for intracranial hemorrhage in outpatients taking warfarin, Ann. Intern. Med, vol.120, pp.897-902, 1994.

P. B. Nielsen, T. B. Larsen, and G. Lip, All Types of Hemorrhagic Stroke Are Not Created Equally-Reply, JAMA Intern. Med, vol.177, p.1399, 2017.

K. C. Thomopoulos, K. P. Mimidis, and G. J. Theocharis, Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy: endoscopic findings, clinical management and outcome, World J. Gastroenterol, vol.11, pp.1365-1373, 2005.

G. Palareti, N. Leali, and S. Coccheri, Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT), Lancet, vol.348, pp.423-431, 1996.

R. J. Beyth, L. M. Quinn, and C. S. Landefeld, Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin, Am. J. Med, vol.105, pp.91-99, 1998.

M. Levi, G. K. Hovingh, and S. C. Cannegieter, Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based, Blood, vol.111, pp.4471-4476, 2008.

S. D. Fihn, M. Mcdonell, and D. Martin, Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group, Ann. Intern. Med, vol.118, pp.511-531, 1993.

C. S. Landefeld and L. Goldman, Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy, Am. J. Med, vol.87, pp.144-52, 1989.

T. I. Shireman, J. D. Mahnken, and P. A. Howard, Development of a contemporary bleeding risk model for elderly warfarin recipients, Chest, vol.130, issue.5, pp.1390-1396, 2006.

M. J. Gitter, T. M. Jaeger, T. M. Petterson, B. J. Gersh, and M. D. Silverstein, Bleeding and thromboembolism during anticoagulant therapy: a population-based study in

M. Rochester, Mayo Clin. Proc, vol.70, pp.725-758, 1995.

M. C. Fang, A. S. Go, and Y. Chang, A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation)

, Study. J. Am. Coll. Cardiol, vol.58, pp.395-401, 2011.

R. Pisters, D. A. Lane, and R. Nieuwlaat, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey, Chest, vol.138, pp.1093-1100, 2010.

B. F. Gage, Y. Yan, and P. E. Milligan, Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF), Am. Heart J, vol.151, pp.713-719, 2006.

P. M. Kuijer, B. A. Hutten, M. H. Prins, and H. R. Büller, Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism, Arch. Intern. Med, vol.159, pp.457-60, 1999.

N. Ruíz-giménez, C. Suárez, and R. González, Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry, Thromb. Haemost, vol.100, pp.26-31, 2008.

F. A. Klok, S. Barco, and S. V. Konstantinides, External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism, Thromb. Haemost, vol.117, pp.1164-1170, 2017.

F. A. Klok, C. Niemann, and C. Dellas, Performance of five different bleedingprediction scores in patients with acute pulmonary embolism, J. Thromb. Thrombolysis, vol.41, pp.312-320, 2015.

M. C. Fang, Y. Chang, and E. M. Hylek, Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation

, Ann. Intern. Med, vol.141, pp.745-52, 2004.

E. M. Hylek, A. S. Go, and Y. Chang, Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation, N. Engl. J. Med, vol.349, pp.1019-1045, 2003.

M. W. Reynolds, K. Fahrbach, and O. Hauch, Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis, Chest, vol.126, pp.1938-1983, 2004.

G. Palareti, N. Leali, and S. Coccheri, Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT), Lancet, vol.348, pp.423-428, 1996.

G. Pernod, A. Godiér, C. Gozalo, B. Tremey, and P. Sié, French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations ( overdose , risk of bleeding , and active bleeding ), Thromb. Res, vol.126, pp.167-174, 2010.

N. A. Limdi, T. M. Beasley, and M. F. Baird, Kidney function influences warfarin responsiveness and hemorrhagic complications, J. Am. Soc. Nephrol, vol.20, pp.912-933, 2009.

D. A. Mcmahan, D. M. Smith, M. A. Carey, and X. H. Zhou, Risk of major hemorrhage for outpatients treated with warfarin, J. Gen. Intern. Med, vol.13, pp.311-317, 1998.

G. Palareti, J. Hirsh, and C. Legnani, Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study, Arch. Intern. Med, vol.160, pp.470-478, 2000.

M. Debray, E. Pautas, P. Couturier, A. Franco, and V. Siguret,

, La Rev. Med. interne, vol.24, pp.107-124, 2003.

C. S. Landefeld and R. J. Beyth, Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention, Am. J. Med, vol.95, pp.315-343, 1993.

T. Wollin, B. Laroche, and K. Psooy, Canadian guidelines for the management of asymptomatic microscopic hematuria in adults, Can. Urol. Assoc. J, vol.3, pp.77-80, 2009.

J. H. Gurwitz, J. Avorn, D. Ross-degnan, I. Choodnovskiy, and A. J. , Aging and the anticoagulant response to warfarin therapy, Ann. Intern. Med, vol.116, pp.901-905, 1992.

C. Billionnet, G. Maura, P. Ricordeau, A. Weill, and F. Alla, Patients initiant un traitement par nouveaux anticoagulants oraux et en situation de risque hémorragique en France au dernier trimestre 2012 : étude d'utilisation sur les données du Sniiram-PMSI, Rev. Epidemiol. Sante Publique, vol.62, p.83, 2014.

G. S. Alotaibi, C. Wu, A. Senthilselvan, and M. S. Mcmurtry, Secular Trends in Incidence and Mortality of Acute Venous Thromboembolism: The AB-VTE Population-Based Study, Am. J. Med, 2016.

G. Sébahoun, Hématologie clinique et biologique. Arnette, 2005.

M. S. Dzeshka and G. Lip, Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation, Heart Fail. Clin, vol.12, pp.257-271, 2016.

B. Boneu and J. Cazenave, Introduction à l'étude de l'hémostase et de la thrombose, 1997.

T. Bombeli and D. R. Spahn, Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage, Br. J. Anaesth, vol.93, pp.275-87, 2004.

A. T. Cohen, M. Hamilton, and S. A. Mitchell, Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis, PLoS One, vol.10, p.144856, 2016.

T. Y. Wang, L. A. Robinson, and F. Ou, Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry, Am. Heart J, vol.155, pp.361-368, 2008.

B. Bonniec and . Le, La cible de la warfarine identifiée. médecine/sciences, 2004.

B. Tremey, Épidémiologie des accidents hémorragiques survenant chez les patients sous antivitamine K, J. Eur. des Urgences, vol.22, pp.1-4, 2009.

J. Ansell, J. Hollowell, and V. Pengo, Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic nonvalvular atrial fibrillation: the international study of anticoagulation management (ISAM), J. Thromb. Thrombolysis, vol.23, pp.83-91, 2007.

J. Ansell, J. Hirsh, and E. Hylek, Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), Chest, vol.133, pp.160-198, 2008.

. Ansm, Evolution des ventes des anticoagulants oraux en France de janvier 2008 à septembre, pp.1-5, 2013.

G. Renda, M. Di-nicola, D. Caterina, and R. , Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials, Am. J. Med, vol.128, pp.1007-1014, 2015.

J. Douketis, Pharmacologic properties of the new oral anticoagulants: a clinicianoriented review with a focus on perioperative management, Curr. Pharm. Des, vol.16, pp.3436-3441, 2010.

B. P. Krijthe, A. Kunst, and E. J. Benjamin, Projections on the number of individuals with atrial fibrillation in the European Union, Eur. Heart J, vol.34, pp.2746-2751, 2000.

X. Delavenne, S. Laporte, and P. Mismetti, New oral anticoagulants: pharmacological data to know for clinical practice, Rev. Med. Suisse, vol.10, pp.319-343, 2014.

M. Loriot and P. Beaune, Pharmacogenetics of oral anticoagulants: individualized drug treatment for more efficacy and safety, Rev. Prat, vol.57, pp.1281-1287, 2007.

L. Bodin, C. Verstuyft, and D. Tregouet, Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity, Blood, vol.106, pp.135-175, 2005.

M. K. Higashi, D. L. Veenstra, and L. M. Kondo, Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy, JAMA, vol.287, pp.1690-1698, 2002.

N. A. Limdi, T. M. Beasley, and M. R. Crowley, VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans, vol.9, pp.1445-58, 2008.

A. Pavani, S. M. Naushad, and B. A. Stanley, Mechanistic insights into the effect of CYP2C9*2 and CYP2C9*3 variants on the 7-hydroxylation of warfarin, Pharmacogenomics, vol.16, pp.393-400, 2015.

P. H. Reitsma, J. F. Van-der-heijden, A. P. Groot, F. R. Rosendaal, and H. R. Büller, A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk, PLoS Med, vol.2, p.312, 2005.

D. J. Harrington, R. Gorska, and R. Wheeler, Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1, J. Thromb. Haemost, vol.6, pp.1663-70, 2008.

V. Siguret, Vitamine K: métabolisme, éléments de physiopathologie, implication dans la variabilité inter-et intra-individuelle de la réponse au traitement par les antivitamines K, Hématologie, 2006.

N. A. Limdi, G. Mcgwin, and J. A. Goldstein, Influence of CYP2C9 and VKORC1

, 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin, vol.83, pp.312-333, 2008.

L. Becquemont, Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice, Eur. J. Clin. Pharmacol, vol.64, pp.953-60, 2008.

M. J. Rieder, A. P. Reiner, and B. F. Gage, Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose, N. Engl. J. Med, vol.352, pp.2285-93, 2005.

L. Wang, H. L. Mcleod, and R. M. Weinshilboum, Genomics and Drug Response, N. Engl. J. Med, vol.364, pp.1144-1153, 2011.

C. Moreau, V. Siguret, and M. Loriot, The pharmacogenetics of vitamin K antagonists: still a matter for discussion

, La Rev. Med. interne, vol.31, pp.361-369, 2010.

E. Thervet, M. A. Loriot, and S. Barbier, Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing, Clin. Pharmacol. Ther, vol.87, pp.721-727, 2010.

L. Wang, N. Raghavan, and K. He, Sulfation of o-demethyl apixaban: enzyme identification and species comparison, Drug Metab. Dispos, vol.37, pp.802-810, 2009.

C. Dimatteo, D. 'andrea, G. Vecchione, and G. , Pharmacogenetics of dabigatran etexilate interindividual variability, Thromb. Res, vol.144, pp.1-5, 2016.

C. L. Preston and I. H. Stockley, Stockley's drug interactions : a source book of interactions, their mechanisms, clinical importance, and management

A. M. Holbrook, J. A. Pereira, and R. Labiris, Systematic overview of warfarin and its drug and food interactions, Arch. Intern. Med, vol.165, pp.1095-106, 2005.

S. C. Sweetman, Martindale : the complete drug reference, 2009.

P. S. Wells, A. M. Holbrook, N. R. Crowther, and J. Hirsh, Interactions of warfarin with drugs and food, Ann. Intern. Med, vol.121, pp.676-83, 1994.

, United Kingdom): European Medicines Agency (EMA), Pradaxa Summary of Product Characteristics, 2008.

A. G. Bayer-pharma, Xarelto®: summary of product characteristics. last Updat, 2013.

, European Medicines Agency. Eliquis Summary of Product Characteristics, pp.1-29, 2011.

J. W. Eikelboom, L. Wallentin, and S. J. Connolly, Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationClinical Perspective, Circulation, vol.123, pp.2363-2372, 2011.

E. M. Hylek, C. Evans-molina, C. Shea, L. E. Henault, and S. Regan, Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation, Circulation, vol.115, pp.2689-2696, 2007.

J. D. Douketis, K. Arneklev, and S. Z. Goldhaber, Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding, Arch. Intern. Med, vol.166, pp.853-862, 2006.

M. Redwood, C. Taylor, B. J. Bain, and J. H. Matthews, The association of age with dosage requirement for warfarin, Age Ageing, vol.20, pp.217-237, 1991.

E. M. Hylek, Oral anticoagulants. Pharmacologic issues for use in the elderly, Clin. Geriatr. Med, vol.17, pp.1-13, 2001.

W. Mueck, S. Schwers, and J. Stampfuss, Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring, Thromb. J, vol.11, p.10, 2013.

E. Abrahams and M. Silver, The History of Personalized Medicine, Integr. Neurosci. Pers. Med, pp.3-16, 2010.

J. T. Jørgensen, New era of personalized medicine: a 10-year anniversary, Oncologist, vol.14, pp.557-565, 2009.

, Personalised Medicine for the European citizen : European Science Foundation

E. To, P. Den, and . Ion-a-t, Executive Office of the President President ' s Council of Advisors on Science and Technology, Pcast, p.108, 2010.

A. D. Hingorani, . Windt-da-v.-d, and R. D. Riley, Prognosis research strategy (PROGRESS) 4: Stratified medicine research, BMJ, vol.346, pp.5793-5793, 2013.

A. Chakravarti, Genomics Is Not Enough. Science (80-. ), vol.334, issue.6052, pp.15-15, 2011.

R. Thiébaut, B. Hejblum, and L. Richert, The analysis of &quot, Rev. Epidemiol. Sante Publique, vol.62, pp.1-4, 2014.

C. I. Fisher and B. Hill, Int. J. Epidemiol, vol.32, pp.922-926, 2003.

T. Poynard, M. Munteanu, and V. Ratziu, Truth survival in clinical research: an evidence-based requiem?, Ann. Intern. Med, vol.136, pp.888-95, 2002.

. Elixhauser-a, C. Steiner, D. R. Harris, and R. M. Coffey, Comorbidity measures for use with administrative data, Med. Care, vol.36, pp.8-27, 1998.

H. Maisonneuve and G. Babany, Données de vie réelle et recherche clinique : le complément des données des essais randomisés, Presse Med, 2015.

L. P. Garrison, P. J. Neumann, P. Erickson, D. Marshall, and C. D. Mullins, Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report, Value Health, vol.10, pp.326-361, 2007.

P. D. Stein and J. W. Henry, Clinical characteristics of patients with acute pulmonary embolism stratified according to their presenting syndromes, Chest, vol.112, pp.974-983, 1997.

S. Z. Goldhaber, L. Visani, D. Rosa, and M. , Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER), Lancet, vol.353, pp.1386-1395, 1999.

K. E. Minges, B. Bikdeli, and Y. Wang, National Trends in Pulmonary Embolism Hospitalization Rates and Outcomes for Adults Aged ?65 Years in the United States, Am. J. Cardiol, vol.116, pp.1436-1442, 1999.

B. Park, L. Messina, and P. Dargon, Recent Trends in Clinical Outcomes and Resource Utilization for Pulmonary Embolism in the United States, Chest, vol.136, pp.983-990, 2009.

I. Tzoran, B. Brenner, M. Papadakis, D. Micco, P. Monreal et al., What Can Be Learned from RIETE? Rambam Maimonides Med, J, vol.5, p.37, 2014.

F. Moustafa, R. Pesavento, and P. Di-micco, Real-life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants, Clin. Pharmacol. Ther, 2017.

R. E. Sherman, S. A. Anderson, and G. J. Dal-pan, Real-World Evidence -What Is It and What Can It Tell Us?, N. Engl. J. Med, vol.375, pp.2293-2297, 2016.

D. L. Bhatt, J. P. Drozda, and D. M. Shahian, ACC/AHA/STS Statement on the Future of Registries and the Performance Measurement Enterprise, J. Am. Coll. Cardiol, vol.66, pp.2230-2245, 2015.

V. J. Bufalino, F. A. Masoudi, and S. K. Stranne, The American Heart Association's recommendations for expanding the applications of existing and future clinical registries: a policy statement from the, American Heart Association. Circulation, vol.123, pp.2167-79, 2011.

A. K. Gitt, H. Bueno, and N. Danchin, The role of cardiac registries in evidence-based medicine, Eur. Heart J, vol.31, pp.525-534, 2010.

M. Monreal, I. Mahe, and A. Bura-riviere, Pulmonary embolism: Epidemiology and registries, Press. Medicale, vol.44, pp.377-383, 2015.

G. Pernod, A. Godiér, and C. Gozalo, French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding), Thromb. Res, vol.126, pp.167-74, 2010.

, Prise en charge des surdosages en antivitamines K des situations à risuqe hémorragique et des accidents hémorragiques chez les patiens traites par AVK en ville et en milieu hospitalier, Has, vol.33, pp.1-4, 2008.

S. Schulman and C. Kearon, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients, J. Thromb. Haemost, vol.3, pp.692-694, 2005.

S. Kaatz, D. Ahmad, A. C. Spyropoulos, and S. Schulman, Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous the ISTH, J. Thromb. Haemost, vol.13, pp.2119-2126, 2015.

F. Moustafa, R. Malhomme, and B. Pereira, Assessment of the Impact of l-Thyroxine Therapy on Bleeding Risk in Patients Receiving Vitamin K Antagonists, Clin. Drug Investig, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01744148

G. Palareti and B. Cosmi, Bleeding with anticoagulation therapy -Who is at risk, and how best to identify such patients, Thromb. Haemost, vol.102, pp.268-278, 2009.

S. Laporte, P. Mismetti, and H. Décousus, Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry, Circulation, vol.117, pp.1711-1717, 2008.
URL : https://hal.archives-ouvertes.fr/ujm-00439761

R. Lecumberri, S. Soler, D. Toro, and J. , Effect of the time of diagnosis on outcome in patients with acute venous thromboembolism: Findings from the RIETE registry, Thromb. Haemost, vol.105, pp.45-51, 2011.

D. Jiménez, D. Miguel-díez, J. Guijarro, and R. , Trends in the Management and Outcomes of Acute Pulmonary Embolism Analysis from the RIETE Registry, J. Am

, Coll. Cardiol, vol.67, pp.162-170, 2016.

R. Morillo, D. Jiménez, and M. Á. Aibar, DVT Management and Outcome Trends, Chest, vol.150, pp.374-83, 2001.
URL : https://hal.archives-ouvertes.fr/hal-01872008

A. Riera-mestre, D. Jimenez, and A. Muriel, Thrombolytic therapy and outcome of patients with an acute symptomatic pulmonary embolism, J. Thromb. Haemost, vol.10, pp.751-759, 2012.

D. Jiménez, A. Muriel, M. Monreal, and R. D. Yusen, Reply: Immortal time bias and the use of IVC filters, J. Am. Coll. Cardiol, vol.64, pp.955-961, 2014.

L. López-jiménez, M. Montero, and J. A. González-fajardo, Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE), Haematologica, vol.91, pp.1046-51, 2006.

A. Blanco-molina, L. L. Rota, D. Micco, and P. , Venous thromboembolism during pregnancy, postpartum or during contraceptive use, Thromb. Haemost, vol.103, pp.306-311, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00722015

J. L. Lobo, J. A. Nieto, and V. Zorrilla, Venous thromboembolism in patients with intracranial haemorrhage, Thromb. Haemost, vol.106, pp.750-752, 2011.

F. Moustafa, S. Fernández, and C. Fernández-capitán, Uterine bleeding during anticoagulation in women with venous thromboembolism, Thromb. Res, vol.151, pp.1-5, 2017.

N. De-crem, K. Peerlinck, and T. Vanassche, Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to Vitamin K antagonists, Thromb. Res, vol.136, pp.749-753, 2015.

L. Whitaker and H. Critchley, Abnormal uterine bleeding, Best Pract. Res. Clin. Obstet. Gynaecol, vol.34, pp.54-65, 2016.

A. Maas, M. Euler, . Von, and M. Y. Bongers, Practice points in gynecardiology: Abnormal uterine bleeding in premenopausal women taking oral anticoagulant or antiplatelet therapy, Maturitas, vol.82, pp.355-359, 2015.

M. Ferreira, S. Barsam, and J. P. Patel, Heavy menstrual bleeding on rivaroxaban, Br. J. Haematol, issue.2, pp.1-2, 2015.

F. Y. Huq, K. Tvarkova, A. Arafa, and R. A. Kadir, Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation, Contraception, vol.84, pp.128-160, 2011.

I. S. Fraser, S. Langham, and K. Uhl-hochgraeber, Health-related quality of life and economic burden of abnormal uterine bleeding, Expert Rev. Obstet. Gynecol, vol.4, pp.179-189, 2009.

M. Shapley, K. Jordan, and P. R. Croft, An epidemiological survey of symptoms of menstrual loss in the community, Br. J. Gen. Pract, vol.54, pp.359-63, 2004.

C. B. Granger, V. Vogel, and S. R. Cummings, Do we need to adjudicate major clinical events?, Clin. Trials, vol.5, pp.56-60, 2008.

J. Pogue, S. D. Walter, and S. Yusuf, Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs, Clin. Trials, vol.6, pp.239-251, 2009.

A. Holbrook, S. Schulman, and D. M. Witt, Antithrombotic therapy and prevention of thrombosis, Chest, vol.141, 2012.

D. R. Spahn, B. Bouillon, and V. Cerny, Management of bleeding and coagulopathy following major trauma: an updated European guideline, Crit. Care, vol.17, p.76, 2013.

F. Moustafa, J. Saint-denis, and S. Laporte, Comparison of blood coagulation factors between patients with gastrointestinal or intracranial bleeding under vitamin K antagonists, Eur. J. Intern. Med, vol.0, pp.893-900, 2016.

R. Sarode, T. J. Milling, and M. A. Refaai, Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: A randomized, plasma-controlled, phase IIIb study, Circulation, vol.128, pp.1234-1243, 2013.

K. Tazarourte, B. Riou, and B. Tremey, Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study), Crit. Care, vol.18, p.81, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-00997767

P. Chowdary, P. Chowdhury, and A. G. Saayman, Efficacy of standard dose and 30

, ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients, Br. J. Haematol, vol.125, pp.69-73, 2004.

I. Tzoran, M. Papadakis, and B. Brenner, Outcome of patients with venous thromboembolism and Factor V Leiden or Prothrombin 20210 mutations during the course of anticoagulation, Am. J. Med, 2016.

V. Roldan, R. Lecumberri, and J. Muñoz-torrero, Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry, Thromb. Res, vol.124, pp.174-181, 2009.

H. R. Büller, G. Agnelli, and R. D. Hull, Antithrombotic Therapy for Venous Thromboembolic Disease, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Therapy, pp.401-428, 2007.

C. Kearon, E. A. Akl, and A. J. Comerota, Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, Chest, vol.141, pp.419-94, 2012.

L. S. Howard and R. J. Hughes, NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing, Thorax, vol.68, pp.391-394, 2013.

F. Moustafa, G. Pierfranceschi, M. , D. Micco, and P. , Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism, Res. Pract. Thromb. Haemost, pp.1-8, 2017.

G. Agnelli, H. R. Buller, and A. Cohen, Oral apixaban for the treatment of acute venous thromboembolism, N. Engl. J. Med, vol.369, pp.799-808, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00932477

. Einstein-pe-investigators, H. R. Büller, and M. H. Prins, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N. Engl. J. Med, vol.366, pp.1287-97, 2012.

, The Hokusai-VTE Investigators. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism, vol.369, pp.1406-1415, 2013.

M. H. Prins, A. W. Lensing, and R. Bauersachs, Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies, Thromb. J, vol.11, p.21, 2013.

Y. Wang, C. Wang, and Z. Chen, Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies, Thromb. J, vol.11, p.25, 2013.

P. M. Kuijer, B. A. Hutten, M. H. Prins, and H. R. Büller, Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism, Arch. Intern. Med, vol.159, pp.457-60, 1999.

C. S. Landefeld and R. J. Beyth, Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention, Am. J. Med, vol.95, pp.315-343, 1993.

C. S. Landefeld and L. Goldman, Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy, Am. J. Med, vol.87, pp.144-52, 1989.

. Nieto, R. Solano, and M. D. Ruiz-ribó, Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: Findings from the RIETE registry, J. Thromb. Haemost, vol.8, pp.1216-1222, 2010.

C. Kearon, E. A. Akl, and J. Ornelas, Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report, Chest, vol.149, pp.315-352, 2016.

L. Hägg, C. Johansson, J. H. Jansson, and L. Johansson, External validity of the ARISTOTLE trial in real-life atrial fibrillation patients, Cardiovasc. Ther, vol.32, pp.214-218, 2014.

S. Apisarnthanarax, S. Swisher-mcclure, and W. K. Chiu, Applicability of randomized trials in radiation oncology to standard clinical practice, Cancer, vol.119, pp.3092-3101, 2013.

C. Saunders, C. D. Byrne, and B. Guthrie, External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?, Diabet. Med, vol.30, pp.300-308, 2013.

F. Moustafa, G. Milhaud, and N. Dublanchet, Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room, J. Mal. Vasc, vol.40, pp.1-9, 2015.

A. T. Cohen, S. Goto, K. Schreiber, and C. Torp-pedersen, Why do we need observational studies of everyday patients in the real-life setting? Eur, Hear. J. Suppl, vol.17, pp.2-8, 2015.

S. F. Assmann, S. J. Pocock, L. E. Enos, and L. E. Kasten, Subgroup analysis and other (mis)uses of baseline data in clinical trials, Lancet, vol.355, pp.1064-1069, 2000.

R. Wang, S. W. Lagakos, J. H. Ware, D. J. Hunter, and J. M. Drazen, Statistics in Medicine -Reporting of Subgroup Analyses in Clinical Trials, N. Engl. J. Med, vol.357, pp.2189-2194, 2007.

M. Carrier, C. Cameron, and A. Delluc, Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis, Thromb. Res, vol.134, pp.1214-1219, 2014.

T. Van-der-hulle, P. L. Exter, and J. Kooiman, Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism, J. Thromb. Haemost, vol.12, pp.1116-1120, 2014.

J. Beyer-westendorf, A. Lensing, and R. Arya, Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials, Thromb. Res, vol.149, pp.29-37, 2017.

C. Becattini and G. Agnelli, Treatment of Venous Thromboembolism with New Anticoagulant Agents, J. Am. Coll. Cardiol, vol.67, pp.1941-1955, 2016.

G. Agnelli, R. Bauersachs, and A. Gitt, P5559: the current use of direct oral anticoagulants (DOACs) for the treatment of VTE in Europe-PREFER in VTE (abstr), Eur Hear. J, vol.35, p.1002, 2014.

A. Gómez-outes, A. I. Terleira-fernández, R. Lecumberri, L. Suárez-gea, M. Vargas-castrillón et al., Direct oral anticoagulants in the treatment of acute venous thromboembolism: A systematic review and meta-analysis, Thromb. Res, vol.134, pp.774-782, 2014.

L. Hood and M. Flores, A personal view on systems medicine and the emergence of proactive P4 medicine: Predictive, preventive, personalized and participatory, N. Biotechnol, vol.29, pp.613-624, 2012.

D. K. Wysowski, P. Nourjah, and L. Swartz, Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action, Arch. Intern. Med, vol.167, pp.1414-1423, 2007.

J. J. Flibotte, N. Hagan, J. O'donnell, S. M. Greenberg, and J. Rosand, Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage, Neurology, vol.63, issue.6, pp.1059-64, 2004.

J. Huhtakangas, S. Tetri, and S. Juvela, Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study, Stroke, vol.42, pp.2431-2436, 2011.

G. Tsivgoulis, V. Lioutas, and P. Varelas, Direct oral anticoagulant-vs vitamin K antagonist-related nontraumatic intracerebral hemorrhage, Neurology, vol.89, pp.1142-1151, 2017.

A. T. Cohen, S. Imfeld, and T. Rider, Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: Comparison and critique of study methodology and results, Adv. Ther, vol.31, pp.473-493, 2014.

S. Apostolakis, D. A. Lane, Y. Guo, H. Buller, and G. Lip, Performance of the HEMORR 2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: The AMADEUS (Evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial, J. Am. Coll. Cardiol, vol.60, pp.861-867, 2012.

F. A. Klok, V. Hösel, and A. Clemens, Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment, Eur. Respir. J, vol.35, pp.419-494, 2016.

. Vii, Annexes Annexe 1: « Comparison of blood coagulation factors between patients with gastrointestinal or intracranial bleeding under vitamin K antagonist

, IF : 2.32) Annexe 5: « Real-Life use of anticoagulants in venous thromboembolism with focus on patients with exclusion criteria for direct oral anticoagulants, Uterine bleeding during anticoagulation in women with venous thromboembolism (SIGAPS D, vol.3, p.132

, Asssessment of the Impact of l-Thyroxine Therapy on Bleeding Risk in patients Receiving Vitamin K Antagonist